Zevra Therapeutics, Inc. (ZVRA) PT Raised to $20 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $21 at Roth/MKM
September 24, 2024 5:40 AM EDTRoth/MKM analyst Jonathan Aschoff raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $21.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "The FDA approved MIPLYFFA for NPC. As ZVRA needs about eight to 12 weeks to make the drug commercially... More
